Overall Status

Not yet recruiting (12)

Recruiting (12)

Active, not recruiting (2)

Completed (1)

Suspended (1)

Withdrawn (1)

Phase

phase 2 (14)

phase 1/phase 2 (9)

phase 3 (3)

phase 1 (2)

phase 2/phase 3 (1)

Collaborator

Incyte Corporation (8)

National Cancer Institute (NCI) (3)

BeiGene (2)

MorphoSys AG (2)

ICON Clinical Research (1)

Ipsen (1)

Oregon Health and Science University (1)

Study Documents

Intervention Type

drug (29)

biological (10)

procedure (7)

other (2)

Funder Type

Other (15)

Industry (14)

Study Type

Interventional (29)

tafasitamab

Showing 26 - 29 of 29

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Relapsed or Refractory DLBCL Trial in United States (Selinexor, Rituximab, Bendamustine)

Suspended

Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Selinexor
+9 more

Tucson, Arizona
+17 more

Jan 24, 2023

Diffuse Large B-cell Lymphoma Trial in Worldwide (Tafasitamab, Lenalidomide, Rituximab)

Recruiting

Diffuse Large B-cell Lymphoma

Tafasitamab
+8 more

Birmingham, Alabama
+408 more

Aug 23, 2022

Follicular Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (tafasitamab, rituximab, lenalidomide)

Recruiting

Follicular Lymphoma
Marginal Zone Lymphoma

tafasitamab
+3 more

Concord, California
+255 more

Dec 1, 2022

Lymphoma, Non-Hodgkin Trial in Worldwide (CC-99282, Rituximab, Obinutuzumab)

Recruiting

Lymphoma, Non-Hodgkin

CC-99282
+4 more

Los Angeles, California
+86 more

Jan 23, 2023